BioSpace News Archive

Abbott will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021. Robert B. Ford, president and chief executive officer, will present at 9 a.m. Central time.

Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover Thera S kin for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds. “This favorable decision by the second larges

Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group ‘s healthcare business headquartered in Tokyo, Japan , and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing , China , jointly announced that they have entered into a strategic col

RedHawk Holdings Corp. (OTC: SNDD) (“RedHawk” or the “Company”), a diversified holding company primarily engaged in sales and distribution of medical devices, announced today financial results for the quarter ended September 30, 2020 , including an 800% increase in revenues for the quarter ended September 30, 2020 when compared

In collaboration with Australian researchers, The Marine Mammal Center in Sausalito, CA has found that the increasing frequency and severity of storm systems drastically decrease the salinity of coastal waters, causing fatal skin disease in dolphins worldwide.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for progressive MS.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI), effective prior to market open on Monday, December 21, 2020.

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) (the “Company”), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has commenced preliminary discussions to amalgamate Antibe Holdings Inc. (“Holdings”) with the Company in order to unify the intellectual property (“IP”) ownership of the Company’s drugs and platform

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a license agreement with SciClone Pharmaceuticals International Ltd (“SciClone”) to be the exclusive co-development and commercialization partner of the Company’s antibodies, DANYELZA

Acquisition Enhances Company’s Decentralized Solutions Offering by Strengthening Patient Focus